ascopubs.org

Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective ...

Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a ...
Renal & Urology News

Combo May Be an Option for Urothelial Carcinoma Patients Who Are Ineligible for Full-Dose Cisplatin

The median duration of response was 9.2 months. The combination of atezolizumab and split doses of cisplatin and gemcitabine can produce durable responses in patients with locally advanced or ...
ascopubs.org

Split-Dose Cisplatin Plus Atezolizumab for Patients With Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA)

Between January 2021 and March 2022, 66 patients were included. The OR was 48.5% (95% CI, 36 to 61), with seven (10.61%) patients experiencing complete response. The median DoR was 9.2 months (95% CI, ...
CURE

FDA Accepts Application for Padcev Plus Keytruda For Some With Bladder Cancer

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
MedPage Today on MSN

'Remarkable' Survival Outcomes in Cisplatin-Ineligible Bladder Cancer

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...